Alexion Pharma (Switzerland)

Alexion Pharma (Switzerland)

Alexion Pharmaceuticals, Inc., a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Alexion Pharma (Switzerland), Switzerland, covering academic research published from 2000 to 2024. Read More.


Open Access Percentage

34%


Total
Publications

327


Total Open
Publications

111


Total
Citations

6.5K


Open Access
Percentage

34%


Total
Publications

327


Total Open
Publications

111


Total
Citations

6.5K

Wikipedia

Website

download

Breakdown

16% 13% 5% 66%

Publisher Open

16%

Both

13%

Other Platform Open

5%

Closed

66%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

051015202530Total Publications
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Open

Closed

Publisher Open

36%OA Journal

OA Journal 36%

34

Hybrid 25%

23

No Guarantees 39%

36

Other Platform Open

Domain 75%

45

Institution 25%

15

Other Internet 8%

5

Public 5%

3

Preprint 3%

2

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
45
Europe PMC
Domain
24
Ghent University - Ghent University Academic Bibliography
Institution
4
University of Groningen / Centre for Information Technology - University of Groningen research database
Institution
2
University of Geneva - Archive ouverte UNIGE
Institution
2
Semantic Scholar
Public
2
Le Centre pour la Communication Scientifique Directe - HAL - TYPE ART
Other Internet
2
Le Centre pour la Communication Scientifique Directe - HAL - Archive ouverte HAL
Institution
2
DOI
Other Internet
2
California Digital Library - eScholarship
Other Internet
2
1 / 3

Data updated 7 April 2025